BAVA.CO - Bavarian Nordic A/S
| Previous Close | 202.40 |
| Open | 199.95 |
| Bid | 203.60 x 0 |
| Ask | 203.80 x 0 |
| Day's Range | 199.20 - 204.30 |
| 52 Week Range | 171.00 - 411.00 |
| Volume | |
| Avg. Volume | 427,735 |
| Market Cap | 15.822B |
| Beta (5Y Monthly) | 1.39 |
| PE Ratio (TTM) | 47.79 |
| EPS (TTM) | 4.26 |
| Earnings Date | Aug 23, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 354.38 |
GlobeNewswireReport of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such
COPENHAGEN, Denmark, May 23, 2023 – Bavarian Nordic A/S (OMX: BAVA) has today received information about the following transactions of the company’s shares/related securities by persons holding managerial responsibilities and/or persons/companies closely associated with such. 1.Details of the person discharging managerial responsibilities/person closely associated a)NameJean-Christophe May2.Reason for the notificationa)Position/statusExecutive Vice President and Chief Commercial Officer of Bavar
- GlobeNewswire
Capital Increase in Bavarian Nordic A/S as a Result of Employee Warrant Exercise
COPENHAGEN, Denmark, May 23, 2023 – Bavarian Nordic A/S (OMX: BAVA) announced today that the Company's share capital has been increased by nominally DKK 555,430 as a consequence of employees’ exercise of warrants. The capital increase was effected without any pre-emption rights for the existing shareholders of the Company or others. The shares were subscribed for in cash at the following prices per share of nominally DKK 10: 34,598 shares at DKK 142.00, 11,945 shares at DKK 146.60 and 9,000 shar
- Reuters
UPDATE 1-Those at high risk of mpox should get 2 doses of Bavarian Nordic vaccine, US CDC says
The U.S. Centers for Disease Control and Prevention is urging people at high risk of mpox to get two doses of Bavarian Nordic's Jynneos vaccine, based on new evidence from a U.S. study showing that the regimen is more effective at preventing infection than one shot. The study, published on Thursday, offered some of the first evidence on the efficacy of the Jynneos vaccine, which was deployed last year during a global outbreak of mpox that affected more than 30,000 people in the United States. The study of the vaccine's real-world use, conducted between Aug. 19, 2022 and March 31, 2023 among 917 people, showed it was 85.9% effective overall in preventing disease after two doses, compared with 75.2% after one dose.
- Reuters
People at high risk to mpox should get 2 doses of Bavarian Nordic vaccine, US CDC says
The U.S. Centers for Disease Control and Prevention is urging people at high risk of mpox to get two doses of Bavarian Nordic's Jynneos vaccine, based on new evidence from a U.S. study showing that two doses were more effective at preventing infection than one, officials said on Thursday. The study, published on Thursday, offered some of the first evidence on the efficacy of the Jynneos vaccine, which was deployed last year during a global outbreak of mpox that affected more than 30,000 people in the United States.
GlobeNewswireDeutsche Bank ADR Investor Conference: Presentations Now Available for Online Viewing
Company Executives Share Vision and Answer Questions at VirtualInvestorConferences.comNEW YORK, May 18, 2023 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Deutsche Bank Depositary Receipts Virtual Investor Conference (“dbVIC”) held on May 16th and 17th are now available for online viewing. REGISTER NOW AT: https://bit.ly/3Mgr7E2 The company presentations will be available 24/7 for 90 days. Investor
- GlobeNewswire
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program and Termination of Share Buy-Back Program
COPENHAGEN, Denmark, May 17, 2023 – Bavarian Nordic A/S (OMX: BAVA) announces that the share buy-back program, which was announced and initiated on May 9, 2023, has now been terminated, as the intended number of shares under the program has been repurchased. The program was executed in accordance with the provisions of Regulation (EU) No. 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse and supplementing Regulation (EU) 2016/1052 of 8 March 2016, which toge
Motley FoolWhy Emergent BioSolutions Stock Inched Slightly Higher Today
Emergent BioSolutions (NYSE: EBS) has been quite the up-and-down stock of late. On Monday, it had an up session on the market, creeping northward by 1.2% and exceeding the S&P 500's gain of 0.3%. The buyer is Denmark-headquartered peer Bavarian Nordic, which has handed over $270 million for the set of assets.
- GlobeNewswire
International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on May 16th and 17th, 2023
NEW YORK, May 15, 2023 (GLOBE NEWSWIRE) -- Deutsche Bank today announced the lineup for its Depositary Receipts Virtual Investor Conference (“dbVIC”) on Tuesday May 16th and Wednesday, May 17th, featuring live webcast presentations from international companies with American Depositary Receipt (ADR) programs in the US. Representatives from participating companies based in Australia, China, Denmark, France, Germany, Hong Kong, Netherlands, South Africa, Switzerland, and United Kingdom will respond
- GlobeNewswire
Bavarian Nordic Completes Acquisition of Travel Vaccine Portfolio from Emergent BioSolutions
COPENHAGEN, Denmark, May 15, 2023 – Bavarian Nordic A/S (OMX: BAVA) announced today that it has completed its acquisition of the travel vaccine portfolio from Emergent BioSolutions Inc. (NYSE: EBS) (“Emergent”). With the closing of this transaction, Bavarian Nordic acquires two marketed vaccines – Vivotif® for the prevention of typhoid fever and Vaxchora® for the prevention of cholera as well as a Phase 3 vaccine candidate for the prevention of Chikungunya virus. The acquisition also includes US
- Thomson Reuters StreetEvents
Q1 2023 Emergent BioSolutions Inc Earnings Call
Q1 2023 Emergent BioSolutions Inc Earnings Call
- GlobeNewswire
Bavarian Nordic to present at the dbVIC - Deutsche Bank ADR Virtual Investor Conference on 16 May 2023
Company invites individual and institutional investors, as well as advisors, to attend interactive, real-time virtual eventHELLERUP, Copenhagen, May 10, 2023 (GLOBE NEWSWIRE) -- Bavarian Nordic (XCSE:BAVA.CO) based in Denmark, and focused on the development manufacturing, and commercialization of life-saving vaccines, today announced that Bavarian Nordic, Rolf Sass Sorensen will present at the dbVIC - Deutsche Bank American Depositary Receipt (ADR) Virtual Investor Conference on May 16th. This v
- GlobeNewswire
Bavarian Nordic Launches Share Buy-Back Program to Hedge Incentive Scheme Obligations
COPENHAGEN, Denmark, May 9, 2023 – Bavarian Nordic A/S (OMX: BAVA) announced today the initiation of a new share buy-back program, under which the Company intends to buy back up to 43,954 of its own shares. The purpose of the share buy-back program is to meet the Company’s obligations arising from the share-based incentive programs for the Board of Directors and Executive Management, in accordance with the Company’s remuneration policy. The share buy-back program is initiated pursuant to the aut
- GlobeNewswire
Bavarian Nordic Announces Interim Results for the First Three Months of 2023
COPENHAGEN, Denmark, May 9, 2023 – Bavarian Nordic A/S (OMX: BAVA) announced today its interim financial results and business progress for the first three months of 2023. Paul Chaplin, President & Chief Executive Officer of Bavarian Nordic said: “We are pleased to report strong results from the first quarter, driven by the continued deliveries of mpox vaccines to countries worldwide combined with a strong performance in our travel vaccine business. The major highlight for the quarter was the ann
- GlobeNewswire
Bavarian Nordic Completes Case Accrual for RSV Phase 3 Clinical Trial
Pivotal Phase 3 trial of MVA-BN® RSV has accrued enough cases required for efficacy analysisTopline results expected around mid-2023 COPENHAGEN, Denmark, April 11, 2023 – Bavarian Nordic A/S (OMX: BAVA) announced today that the Phase 3 clinical trial of MVA-BN® RSV, the Company’s investigational vaccine for the prevention of respiratory syncytial virus (RSV) in adults ≥60 years of age, has now accrued the number of cases required to complete the primary efficacy analysis, which is expected aroun
- GlobeNewswire
Resolutions of the Annual General Meeting 2023 of Bavarian Nordic A/S
COPENHAGEN, Denmark, March 30, 2023 – Bavarian Nordic A/S (OMX: BAVA) today held the Annual General Meeting with the following results: The Annual Report for 2022 was adopted. The Board of Directors’ proposal to transfer the Company’s result to 2023 was also adopted.The Remuneration Report for 2022 was approved.The Board of Directors and the Board of Management were discharged from liability.Anders Gersel Pedersen, Peter Kürstein, Frank Verwiel, and Anne Louise Eberhard were re-elected, and Luc
- GlobeNewswire
Bavarian Nordic A/S – Notice Convening Annual General Meeting
COPENHAGEN, Denmark, March 7, 2023 – Pursuant to Articles 10-14 of the Articles of Association, the shareholders of Bavarian Nordic A/S are hereby convened to the Annual General Meeting to be held on Thursday, 30 March 2023, at 4 PM CEST at Comwell Borupgaard, Nørrevej 80, DK-3070 Snekkersten, Denmark with the following agenda: The Board of Directors' report on the Company's activities in the past year.Presentation of the Annual Report for adoption.A proposal from the Board of Directors regardin
- GlobeNewswire
Bavarian Nordic Publishes Annual Report 2022
COPENHAGEN, Denmark, March 2, 2023 – Bavarian Nordic A/S (OMX: BAVA) today published its Annual Report for 2022. The consolidated, audited results were in line with the preliminary results, announced on January 16, 2023. The full report is attached as a PDF file and can be found on the company's website, www.bavarian-nordic.com. Paul Chaplin, President & Chief Executive Officer of Bavarian Nordic said: “We proudly delivered all-time high revenues in 2022 resulting from significant deliveries of
- GlobeNewswire
Bavarian Nordic to Host Full Year 2022 Results Conference Call
COPENHAGEN, Denmark – February 24, 2023 - Bavarian Nordic A/S (OMX: BAVA) will publish its 2022 annual report on Thursday, March 2, 2023. The management of Bavarian Nordic will host a conference call at 2:00 pm CET (8:00 am EST) on the same day to present the full-year results followed by a Q&A session. A listen-only version of the call and presentation slides can be accessed via http://bit.ly/3lSQ92A. To join the Q&A session, please register in advance via http://bit.ly/3IQRBLV. About Bavarian
- GlobeNewswire
Bavarian Nordic A/S - Registration of Share Capital Increase of 7,046,839 New Shares Completed
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO THE UNITED STATES, CANADA, JAPAN, SOUTH AFRICA, HONG KONG OR AUSTRALIA, EXCEPT AS PERMITTED BY APPLICABLE LAW, OR IN ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION IS UNLAWFUL. COPENHAGEN, Denmark, February 23, 2023 – Bavarian Nordic A/S (OMX: BAVA) ("Bavarian Nordic" or the "Company") has in connection with the directed issue and private placement today registered with the Danish Business Auth
- Reuters
UPDATE 1-CDC panel recommends Bavarian Nordic's mpox vaccine for all adults at risk
The panel of outside experts voted unanimously in favor of use of two doses of the vaccine, and finalizing the interim guidelines provided by CDC during the mpox outbreak in the United States. The recommendation of the committee is based on studies that showed vaccine effectiveness of 66%-83% for patients with full vaccination and 36%-86% for partial vaccination with no severe adverse affect. The intradermal injection of Jynneos – that is between the layers of skin – is the preferred form of administration for adults during the outbreak, but is also approved as a subcutaneous injection, or below the skin.
- GlobeNewswire
Bavarian Nordic A/S Announces Completion of Directed Issue of 7,046,839 New Ordinary Shares
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO THE UNITED STATES, CANADA, JAPAN, SOUTH AFRICA, HONG KONG OR AUSTRALIA, EXCEPT AS PERMITTED BY APPLICABLE LAW, OR IN ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION IS UNLAWFUL. COPENHAGEN, Denmark, February 20, 2023 – On 20 February 2023, Bavarian Nordic A/S (“Bavarian Nordic” or the “Company”) announced its intention to raise new capital through an accelerated bookbuilding process. The offerin
- GlobeNewswire
Bavarian Nordic A/S Launches Offering of up to 7,046,839 New Shares in a Directed Issue
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO THE UNITED STATES, CANADA, JAPAN, SOUTH AFRICA, HONG KONG OR AUSTRALIA, EXCEPT AS PERMITTED BY APPLICABLE LAW, OR IN ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION IS UNLAWFUL. COPENHAGEN, Denmark, February 20, 2023 – Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) (“Bavarian Nordic” or the “Company”) has resolved to launch an offering (the “Offering”) of new shares (the “New Shares”). The Offering
- Reuters
UPDATE 1-Bavarian Nordic to buy travel vaccine portfolio for up to $380 mln
Danish pharmaceuticals company Bavarian Nordic has agreed to buy a portfolio of travel vaccines from Emergent BioSolutions Inc for up to $380 million, it said on Wednesday after delivering an upbeat outlook for 2023. The company said it would acquire a typhoid fever vaccine, one against cholera and a Chikungunya virus treatment that is in Phase III trials. "Travel vaccines are seeing a rebound after the COVID-19 pandemic," the company said.
ReutersBavarian Nordic to buy travel vaccine portfolio for up to $380 million
Bavarian Nordics makes the only approved mpox vaccine and started receiving massive orders last year as the virus became a global issue. The company expects 2023 revenue of about 6 billion Danish crowns ($863 million) against the 3.15 billion crowns in preliminary 2022 results, with 4.4 billion crowns coming from mpox and smallpox vaccined contracts alone. Earnings before interest, tax, depreciation and amortisation (EBITDA) are expected to reach 2.2 billion crowns this year, up from 329 million crowns in the preliminary results for 2022.
- GlobeNewswire
Bavarian Nordic to Acquire Portfolio of Travel Vaccines from Emergent BioSolutions
Adds two revenue-generating vaccines for the prevention of cholera and typhoid fever that will establish Bavarian Nordic as a global leader in travel vaccinesBroadens development pipeline with a late-stage Chikungunya vaccine candidate with significant synergistic market opportunity in areas with a high unmet medical needExpands manufacturing footprint and flexibility with facility in Switzerland and adds research competences with facility in San Diego, CATotal acquisition price of up to USD 380